| 000 | 01649 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518100312.0 | ||
| 264 | 0 | _c20210112 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-020-06848-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAli, Arwa | |
| 245 | 0 | 0 |
_aCorrelation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial. _h[electronic resource] |
| 260 |
_bBMC cancer _cApr 2020 |
||
| 300 |
_a342 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Observational Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDuration of Therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aOximes _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins B-raf _xgenetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 700 | 1 | _aDumbrava, Monica | |
| 700 | 1 | _aRiddell, Kylie | |
| 700 | 1 | _aStewart, Nina | |
| 700 | 1 | _aWard, Robyn | |
| 700 | 1 | _aIbrahim, Ahmed K | |
| 700 | 1 | _aChin, Melvin | |
| 773 | 0 |
_tBMC cancer _gvol. 20 _gno. 1 _gp. 342 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-020-06848-8 _zAvailable from publisher's website |
| 999 |
_c30887875 _d30887875 |
||